02 March 2019 | Bern, Switzerland
Update in Genitourinary Cancers
Many thanks to everyone, who attended the ASCO Direct™ GU Highlights Meeting in Bern, Switzerland on Saturday, 02 March 2019.
The ASCO Direct GU Highlights Meeting was a full-day educational program containing selected original sessions from the 2019 Genitourinary Cancers Symposium on urothelial carcinoma, prostate, bladder, renal, penile, urethral, and testicular cancers. Attendees had the opportunity to view the original sessions with most actual clinical data in uro-oncology and discuss the clinical relevance and implications for Swiss treatment landscape of the presented evidence with their colleagues.
Here are the program and details of the ASCO Direct™ GU Highlights Meeting 2019. We are looking forward to organize the Highlights meeting 2020, the related information will be available later this year.
If you would like any further information, please feel free to contact us at asco@springer.com
Independent scientific committee
The program is supervised by an independent scientific committee:
- Joerg Beyer, Inselspital Bern
- Martin Spahn, Hirslanden
- Aurelius Omlin, Kantonsspital St. Gallen
- Dominik Berthold, Centre Hospitalier Universitaire Vaudois
Program
Saturday, March 2nd 2019
| 09:00-09:10 | Welcome & Start of the program | |
|---|---|---|
| 09:10-10:10 | Prostate Cancer | |
| Martin Spahn | Diagnostic procedures in prostate cancer diagnosis: State-of-the-art | |
| Andrew Vickers | PSA screening – towards a harm reduction approach | |
| Samir Taneja | The role of MRI in target biopsy | |
| Scott Williams | A randomized trial comparing fluorocholine-PET/CT with conventional imaging in prostate cancer | |
| 10:10-10:30 | Break | |
| 10:30-12:30 | Prostate Cancer | |
| Aurelius Omlin | Controversies in PCa | |
| Nicolas J. Van As | PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa). | |
| Andrew J. Amstrong | Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial. | |
| Karim Fizazi | ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). | |
| Evan Yu | Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). | |
| 12:30-13:30 | Lunch | |
| 13:30-16:00 | Urothelial Bladder Cancer | |
| Jörg Beyer | What are the issues in localized urothelial bladder cancer | |
| Michael Cookson | Radical Cystectomy Is the Best Option for Muscle-Invasive Bladder Cancer | |
| Jason A. Efstathiou | Trimodality Therapy Is the Best Option for Muscle-Invasive Bladder Cancer | |
| Andrea Necchi | Perioperative Immunotherapy in Urothelial Carcinoma: State of Existing Evidence | |
| James L. Gulley | Key Note Lecture: Immunotherapy Across Genitourinary Malignancies | |
| 16:00-16:30 | Break | |
| 16:30-18:00 | Renal Cancer | |
| Dominik Berthold | New standard in RCC: TKI, Immunotherapy or both | |
| Brian M. Shuch | When to Obtain Genetic Testing for Syndromic Renal Cell Cancer | |
| Paul Russo | Lessons learned from Carmena: Surgeon’s Perspective | |
| Lauren C. Harshman | Lessons learned from Carmena: Medical Oncologist’s Perspective | |
| Thomas Powles | Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study | |
| Daniel Y. C. Heng | Beyond First-Line Systemic Therapy for Metastatic Renal Cell Cancer | |
| 18:00-18:20 | Important trials and activities in Switzerland in urogenital cancer in 2018 | |
| Aurelius Omlin | Prostate Cancer | |
| Martin Spahn | Urothelial bladder Cancer | |
| Jörg Beyer | Testicular Cancer | |
| Dominik Berthold | Renal Cell Cancer | |
| 18:20-18:30 | Closing Remarks | |
Program may be subject to change
Registration
The registration fee is 115 CHF and will be donated to the Movember Foundation.
Benefits of this meeting
- No jet lag
- No extended absence from your clinic
- Access to all videos and slides from ASCO GU 2019 via the ASCO® Meeting Library
- Reduced travel time to stay informed about the latest news and developments presented at the ASCO GU symposium
- Discussion with Swiss experts and colleagues
Contact
Please feel free to contact us at asco@springer.com if you have any questions.
Sponsored by:
ASCO Direct™ Highlights is an officially licensed program of the American Society of Clinical Oncology®. ASCO® is a registered trademark of the American Society of Clinical Oncology. All rights reserved. ASCO does not endorse any health care product, therapy, diagnostic test or device.
